TARSUS PHARMACEUTICALS INC. - COMMON STOCK

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

13 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

13 11 2024 08:30:00 提供 Nasdaq GlobeNewswire

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

06 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

05 11 2024 08:30:00 提供 Nasdaq GlobeNewswire

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

17 10 2024 08:30:00 提供 Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

25 9 2024 17:00:00 提供 Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

28 8 2024 17:00:00 提供 Nasdaq GlobeNewswire

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

08 8 2024 16:05:01 提供 Nasdaq GlobeNewswire

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

29 7 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tarsus to Participate in Upcoming Investor Conferences

29 5 2024 17:00:00 提供 Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

09 5 2024 17:00:00 提供 Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

08 5 2024 16:05:01 提供 Nasdaq GlobeNewswire

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

01 5 2024 17:00:00 提供 Nasdaq GlobeNewswire

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

23 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Tarsus to Participate at Upcoming Investor Conferences

05 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

05 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Tarsus Announces Pricing of $100.0 Million Public Offering

01 3 2024 00:07:38 提供 Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Public Offering

29 2 2024 16:37:35 提供 Nasdaq GlobeNewswire

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

27 2 2024 06:00:00 提供 Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

22 2 2024 08:00:00 提供 Nasdaq GlobeNewswire